STAT3 and glioblastoma: Kenchappa et al. find that ispinesib resistance in glioblastoma is due to phosphorylation-mediated activation of STAT3 and that blocking phosphorylation with FDA-approved drugs reverses this resistance and renders ispinesib effective.